ACM
RNAM

Altium Capital Management’s Avidity Biosciences RNAM Stock Holding History

Altium Capital Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-150,000
Closed -$2.45M – 128
2022
Q3 		$2.45M Hold
150,000
– – 0.9% 44
2022
Q2 		$2.18M Sell
150,000
-93,000
-38% -$1.38M 0.87% 46
2022
Q1 		$4.49M Buy
243,000
+18,000
+8% +$306K 1.5% 24
2021
Q4 		$5.35M Hold
225,000
– – 1.47% 19
2021
Q3 		$5.54M Buy
225,000
+36,400
+19% +$791K 1.45% 22
2021
Q2 		$4.66M Buy
188,600
+10,000
+6% +$233K 1.08% 32
2021
Q1 		$3.9M Buy
+178,600
New +$4.37M 1.08% 33

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Altium Capital Management's RNAM Position: Q4 2022 in Review

Altium Capital Management sold out of Avidity Biosciences (RNAM) in Q4 2022, closing a stake of 150,000 shares — an estimated $2.45M sold.

Altium Capital Management first reported a position in RNAM in Q1 2021 and held it in 7 quarters. The position peaked at $5.54M in Q3 2021. 148 funds tracked by Wall St. Rank hold RNAM as of Q4 2022.

  • Altium Capital Management reported no remaining Avidity Biosciences position as of Q4 2022 after selling out during the quarter.
  • Altium Capital Management sold 150,000 Avidity Biosciences shares in Q4 2022, an estimated $2.45M.
  • Altium Capital Management first reported a position in Avidity Biosciences in Q1 2021 and held it in 7 quarters.
  • Altium Capital Management's Avidity Biosciences position peaked at $5.54M in Q3 2021.
  • 148 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2022.

Based on Altium Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.